Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience

Código QR

Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience

Jose M Montes,1 Paloma Montes,2 Daniel Hernández-Huerta3 1Psychiatry Service, CIBERSAM, IRYCIS, Hospital Universitario Ramóny Cajal, Madrid, Spain; 2Psychiatry Service, Hospital Universitario de Móstoles Madrid, Spain; 3Psychiatry Service, Hospital Universitario Ram&...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Montes JM, Montes P, Hernández-Huerta D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	schizophrenia cariprazine antipsychotics negative symptoms case report Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/67129604ad4b4012a2dbf1770babe8cd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Octavian Vasiliu
Publicado: (2021)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel T
Publicado: (2021)

Negative Symptoms of Schizophrenia: New Prospects of Cariprazine Treatment
por: Aleksandr M. Reznik, et al.
Publicado: (2020)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy Á, et al.
Publicado: (2021)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
por: Barabássy Á, et al.
Publicado: (2021)

Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy
por: Citrome L
Publicado: (2018)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts RJ, et al.
Publicado: (2016)

New drugs in psychiatry - cariprazine, lurasidone, esketamine
por: Pożarowska Kinga, et al.
Publicado: (2021)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll CU, et al.
Publicado: (2019)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Borjanka Batinic, et al.
Publicado: (2021)

Elevated activity of superoxide dismutase in male late-life schizophrenia and its correlation with clinical symptoms and cognitive deficits
por: Lijuan Huo, et al.
Publicado: (2021)

Adjunctive simvastatin treatment in schizophrenia patients; a double blind randomized and placebo controlled trial
por: Somaieh Ashrafi, et al.
Publicado: (2022)

Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm
por: Cerveri G, et al.
Publicado: (2019)

Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
por: Müller HHO, et al.
Publicado: (2021)

Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study
por: Liang Y, et al.
Publicado: (2017)

The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2021)

ECT in an Adolescent With Schizophrenia and Seizures: Case Report
por: Anna Gralewicz, et al.
Publicado: (2021)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Chih-Sung Liang, et al.
Publicado: (2021)

Metabolic disturbances in patients with paranoid schizophrenia treated with atypical antipsychotic drugs
por: Leonid Mikhaylovich Bardenshteyn, et al.
Publicado: (2010)

Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection
por: Fitzgerald HM, et al.
Publicado: (2021)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Stephan Hjorth, et al.
Publicado: (2021)

Influence of CFH gene on symptom severity of schizophrenia
por: Zhang C, et al.
Publicado: (2017)

Relationship between social and cognitive functions in people with schizophrenia
por: Tominaga T, et al.
Publicado: (2018)

Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
por: Correll CU, et al.
Publicado: (2020)

Online Left-Hemispheric In-Phase Frontoparietal Theta tACS for the Treatment of Negative Symptoms of Schizophrenia
por: Chuan-Chia Chang, et al.
Publicado: (2021)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
por: Ping Yin, et al.
Publicado: (2021)

Comparison of beta-endorphin and CGRP levels before and after treatment for severe schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2016)

Cognitive dysfunction and negative symptoms in patients with schizophrenia and their first-degree relatives from simplex and multiplex families
por: Zhang Z, et al.
Publicado: (2018)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
por: Montemagni C, et al.
Publicado: (2016)

Diagnosis and Treatment of Depression in Patients with Schizophrenia
por: Sergey N. Mosolov
Publicado: (2020)

Esquizofrenia y su asociación con enfermedades médicas crónicas
por: Orellana,Gricel, et al.
Publicado: (2017)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo R, et al.
Publicado: (2019)

The Relationship between the Second-Generation Antipsychotics Efficacy and the Traditional Chinese Medicine Body Constitutions in Patients with Schizophrenia
por: Tzu-Pei Yeh, et al.
Publicado: (2021)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
por: Zhang LL, et al.
Publicado: (2016)

A systematic review of the effects of psychiatric medications on social cognition
por: Zoë Haime, et al.
Publicado: (2021)

Lack of tolerable treatment options for patients with schizophrenia
por: Citrome L, et al.
Publicado: (2015)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
por: Faden J, et al.
Publicado: (2019)

Suicidality, self-stigma, social anxiety and personality traits in stabilized schizophrenia patients – a cross-sectional study
por: Vrbova K, et al.
Publicado: (2018)

The Effects of Recreation Therapy on the Habit of Smoking and Positive–Negative Symptoms Among Patients with Chronic Schizophrenia
por: Pirbalouti M. G., et al.
Publicado: (2017)